昭栄薬品 has revised upward its consolidated earnings forecast for the second quarter of the fiscal year ending March 2027. The second-quarter forecast has been revised upward to net sales of ¥15.836 billion, operating profit of ¥424 million, ordinary profit of ¥520 million and net profit attributable to owners of the parent of ¥351 million.
昭栄薬品 has raised its consolidated earnings forecast for the second quarter of the fiscal year ending March 2027 from its previous outlook. Its core chemicals business remained strong, with order volumes from major domestic customers exceeding expectations and the pass-through of higher selling prices making progress. As a result, net sales and each profit line are expected to exceed the previous forecast.
Specifically, the forecast has been revised upward to net sales of ¥15.836 billion, up 17.0% from the previous forecast; operating profit of ¥424 million, up 103.3%; ordinary profit of ¥520 million, up 71.4%; and net profit attributable to owners of the parent of ¥351 million, up 71.7%.
The full-year consolidated earnings forecast is currently under review and is scheduled to be announced when the second-quarter results are released on 11 November 2026.